GlycoNex Incorporation
Research GlycoNex Incorporation (4168.TWO) on Bullrun: market cap TWD 2.45B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4168.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 2.45B
- Financial periodQ2 2026
- RevenueTWD 1.90M
- Net income-TWD 55.02M
- Free cash flow-TWD 43.37M
- Gross margin16.5%
Valuation Snapshot
latest market cap is TWD 2.45B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 2.45B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About GlycoNex Incorporation
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company's pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases.
ETFs that hold GlycoNex Incorporation
US-listed ETFs
GlycoNex Incorporation is held by 2 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GlycoNex Incorporation's market cap?
GlycoNex Incorporation's market capitalization is TWD 2.45B.
What does GlycoNex Incorporation do?
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company's pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases.